Fiche centre
Stanford University
Stanford — United States
Essais liés17clinical trials
VilleStanfordlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05481879
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| brexucabtagene autoleucel | SEP | Phase 1 | NCT03624036 | ZUMA-8 — Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | TERMINATED |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| SherpaPak Cardiac Transport System | Insuffisance cardiaque | À vérifier | NCT04141605 | GUARDIAN — Global Utilization And Registry Database for Improved heArt preservatioN | ENROLLING_BY_INVITATION |
| Cilostazol 100 mg Tablets | Accident vasculaire cérébral | Phase 3 | NCT07174414 | Clarity — Cilostazol for Prevention of Recurrent Stroke Trial | NOT_YET_RECRUITING |
| Acoramidis | Alzheimer | Phase 2 | NCT03536767 | Open-Label Study of AG10 in Patients With Cardiomyopathy | TERMINATED |
| KITE-363 | Lupus | Phase 1 | NCT07038447 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | ENROLLING_BY_INVITATION |
| DYNE-101 | Myopathies | Phase 1/2 | NCT05481879 | ACHIEVE — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | ACTIVE_NOT_RECRUITING |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters | Épilepsie | Non applicable | NCT06143293 | RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS | ACTIVE_NOT_RECRUITING |
| Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | Myopathies | À vérifier | NCT06503367 | Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | RECRUITING |
| Partial Nephrectomy (PN) | Cancer | À vérifier | NCT05363657 | i-RECORd — International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors | RECRUITING |
| GBPDC: Gut-Brain in PD Consortium Master Protocol | Parkinson | À vérifier | NCT07567794 | GBPDC: Gut-Brain in PD Consortium Master Protocol | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| Bumetanide | Alzheimer | Phase 2 | NCT06052163 | BumxAD — Bumetanide in Patients With Alzheimer's Disease | RECRUITING |
| The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial | Alzheimer | NA | NCT03313895 | The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial | COMPLETED |